The Fort Worth oncology company tapped former Salarius Pharmaceuticals CEO David Arthur to lead its push toward commercialization, including a planned IND for a rare pediatric brain cancer program.
Ribbon-cutting ceremony for the National Center for Therapeutics Manufacturing satellite campus [Photo: UTA]
Left: Daniel Hargrove, co-founder and CEO of InterAct Therapeutics; Right: Isaac Chan, MD, PhD, Co-founder and CSO of InterAct Therapeutics [Photos: LinkedIn]